CR
CRL
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $0M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Charles River Laboratories International Inc. (CRL) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for CRL — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 49.90 | NEUTRAL |
| Stochastic %K (14) | 14.18 | BUY |
| CCI (20) | -117.13 | BUY |
| Williams %R (14) | -85.82 | BUY |
| MACD (12,26,9) | -4.40 | SELL |
| ROC (10) | -6.72 | SELL |
| Momentum (10) | -19.92 | SELL |
| EMA (10) | 282.52 | SELL |
| SMA (10) | 284.43 | SELL |
| EMA (20) | 280.89 | SELL |
| SMA (20) | 287.73 | SELL |
| EMA (30) | 274.56 | BUY |
| SMA (30) | 279.01 | SELL |
| EMA (50) | 260.18 | BUY |
| SMA (50) | 258.85 | BUY |
| EMA (100) | 234.41 | BUY |
| SMA (100) | 219.15 | BUY |
| EMA (200) | 212.60 | BUY |
| SMA (200) | 202.42 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Charles River Laboratories International Inc.
Healthcare · Diagnostics & Research
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-07-06
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 2 bearish
Average — needs more confirmation before sizing up
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | BEARISH | 37 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
CLUSTER SELL 0 buys · 16 sells
Recent: Girshick Birgit sold 36013 sh @ $279.90 (2026-08-11); FOSTER JAMES C sold 31596 sh @ $300.00 (2026-08-25); FOSTER JAMES C sold 31596 sh @ $275.00 (2026-08-10)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.